1. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine;Heinemann;Mol Pharmacol,1990
2. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells;Ren;Clin Cancer Res,1998
3. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia;Grunewald;Cancer Res,1990
4. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine;Abbruzzese;J Clin Oncol,1991
5. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma;Tempero;J Clin Oncol,2003